Patent Expirations Drive New Oncology Biosimilars Is Supporting Development Across The Oncology Biosimilars Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Oncology Biosimilars Market Through 2030?

The oncology biosimilars market has experienced swift expansion over recent years. This market is projected to expand from $11.35 billion in 2025 to $12.83 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.0%. Historically, this growth can be ascribed to several factors, including the elevated expense of reference biologics, restricted access to oncology biosimilars, rising global cancer incidence, the expansion of hospital and pharmacy infrastructure, and swift regulatory clearances for monoclonal antibody biosimilars.

The oncology biosimilars market is anticipated to experience significant expansion in the coming years. Its value is projected to reach $21.28 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This expansion during the forecast period is driven by factors such as the introduction of novel biosimilar medications including pembrolizumab and pegfilgrastim, the broadening of online pharmacy networks, increased acceptance of immunomodulators and hematopoietic agents, heightened government efforts to enhance access to cancer care, and a growing emphasis on tailored oncology treatments. Key trends for this period encompass the increased uptake of rituximab, trastuzumab, and bevacizumab biosimilars, the expanded application of immunomodulators and hematopoietic agents in cancer therapy, a surge in G-CSF biosimilars for addressing neutropenia, the broadening of hospital and retail pharmacy avenues for oncology biosimilars, and a strong drive towards affordable and readily available cancer therapy choices.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2821&type=smp

What Core Drivers Are Transforming The Oncology Biosimilars Market?

The lapse of patents for biologics utilized in cancer treatment is fostering the development of new oncology biosimilars. Biologics are granted patent protection for a limited timeframe, and the expiration of these patents enables the creation of novel biosimilars. These biologics are targeted medications synthesized from living organisms that stimulate the immune system to attack cancer cells. Biosimilars, while not identical to biologics, possess similar characteristics and offer comparable effectiveness at a reduced cost. For instance, in February 2024, DrugTimes, a Chinese-based company focused on the pharmaceutical and biotech industry, indicated that by 2037, more than 25 products are expected to lose patent protection, potentially leading to a combined revenue decline exceeding $236.4 billion, based on 2024 sales figures. This growing number of patent expiries is projected to enhance the demand for producing new oncology biosimilars, consequently driving growth in the oncology biosimilars market.

What Key Segment Areas Are Included In The Oncology Biosimilars Market Assessment?

The oncology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars

2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars

3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars

4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

Which Trends Are Influencing The Expansion Of The Oncology Biosimilars Market?

Leading companies in the oncology biosimilars market are concentrating on the development of novel cancer therapies, such as targeted biologics and monoclonal antibodies, to improve treatment efficacy, patient outcomes, and overall accessibility in oncology care. Monoclonal antibodies (mAbs) are laboratory-engineered proteins designed to identify and bind specific cancer cell antigens, allowing for precise targeting and immune-driven destruction. A notable example is Pfizer, a US-based pharmaceutical company, which in March 2023 merged with Seagen and invested $43 billion to reinforce its oncology portfolio. This strategic action expands Pfizer’s footprint in cancer therapeutics and accelerates the advancement of sophisticated treatments for cancer, a primary global cause of death. The investment also emphasizes the increasing trend of substantial capital being directed toward innovative oncology biosimilars to meet existing medical needs and broaden global access to cancer care.

Which Organizations Are Operating Within The Oncology Biosimilars Market?

Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

Access The Complete Oncology Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Which Geographic Region Represents The Largest Oncology Biosimilars Market Share?

North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oncology Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2821&type=smp

Browse Through More Reports Similar to the Global Oncology Biosimilars Market 2026, By The Business Research Company

Biosimilar Growth Hormone Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Monoclonal Antibodie Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Biosimilar Therapeutic Peptide Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795